Lipid Nano-Crystal (LNC)

A disruptive platform for the safe and targeted delivery of therapeutics.

Our proprietary intracellular LNC platform is designed to safely deliver a broad range of potent medicines – including small molecules, drugs with blood level-limiting toxicities, nucleic acid polymers, proteins, peptides, vaccines, and gene editing technologies. It is formulated as a natural, non-toxic and highly efficient spiral crystal, or “cochleate,” with the unique ability to be administered orally and through various other routes.

The drug molecules are encapsulated in our layered design, which protects them from harsh environmental conditions or enzymes until the moment they enter a target cell. Following non-destructive fusion with the cell membrane, the molecules are naturally released to the interior of the cell, avoiding the systemic toxicity of other drug platforms.

To date, our platform has been validated in multiple preclinical studies and is protected by a robust IP portfolio. To support all phases of further development, we have begun operating a scalable GMP manufacturing facility.

How it works.

Watch our MOA video to learn how our LNC technology captures and protects the active drug ingredient until it reaches the activated cell.


Drug Encapsulation

Drug Encapsulation

  1. The cochleate is prepared using naturally occurring phospholipids and calcium.
  2. When calcium interacts with the negatively charged lipids, they spiral into non-toxic, highly stable crystalline units with multiple layers and little to no internal aqueous space.
  3. The active drug molecules become trapped within the layers, where they are protected from water and harmful external elements.
Intracellular Release

Intracellular Release

  1. The cochleate is delivered into the body and directly targets the clinically relevant cells.
  2. It then fuses with the cell membrane in a non-destructive manner.
  3. The low calcium environment of the cell’s interior causes the cochleate to unlock and unwind, releasing the drug into the target cell.

Key Features

Our LNC technology was engineered with core characteristics that transform the delivery of certain therapeutics.


icon

SAFE

Delivers molecules in a natural, non-toxic and non-destructive manner without provoking an immune response.

icon

TARGETED

Physiologically targets “activated” cells and enters them directly, helping to maximize efficacy.

icon

ORALLY BIOAVAILABLE

Enables oral administration and easy absorption into the circulatory system through the lymphatics.

icon

STABLE

Resists water penetration, environmental attacks and degradation in the GI tract; increases the stability of drug molecules.

icon

FLEXIBLE

Can administer a wide range of small and large molecules through multiple routes: oral, intravenous, intramuscular, and intranasal.

Traditional vs. LNC Vehicles

We are addressing the delivery challenges of current therapies.

We intend to accomplish three primary goals through our LNC technology – the first being the improvement of the safety profile of drugs that cause excessive off-target organ toxicity. We are additionally facilitating targeted intracellular delivery – an essential method for complex gene therapies. Finally, we are reformulating efficacious, yet inconvenient and/or otherwise toxic IV-administered drugs as oral agents.

Traditional Model

Traditional Model

  • Requires high plasma levels
  • Low amounts of the drug molecules can penetrate the protective cell layers, while the rest are left circulating in the system
  • Potentially results in off-target organ toxicity


TLNC Model

LNC Model

  • Causes low plasma levels
  • Enters cells directly, releasing the drug content into the infected cell membrane
  • Likely to result in less systemic toxicity

Driving opportunities for value-added partnerships.

We are currently working with multiple strategic and research partners to expand potential successful applications of this LNC technology.

In early 2019, we collaborated with a top global pharmaceutical company to sign our first LNC platform research evaluation of oligonucleotide. Later in the year, we entered into a feasibility collaboration with Genentech, a member of the Roche Group, to evaluate various Genentech molecules.

We have also signed research collaborations with both the National Institutes of Health and ViiV Healthcare to further explore the potential of our LNC technology and evaluate the formulation of antiviral drug candidates.

ViiV Healthcare